A brief review on prognostic models of primary biliary cholangitis
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune liver disease characterized by progressive destruction of small intrahepatic bile ducts. If left untreated, PBC may eventually result in end-stage liver disease. For better management of PBC and optimal allocation of medical resources, it is pivotal to accurately estimate the prognosis of patients with PBC. This article will briefly review the models that predict long-term outcome of PBC patients, with special focus on the applicability, strengths and limitations of the widely used models reported from 1983 to 2016. Among many, the Mayo score has been extensively validated and considered as the classic prognostic model for untreated PBC patients, whereas the well-validated Paris I and Paris II criteria are mainly used in ursodeoxycholic acid (UDCA)-treated patients with advanced PBC (stage III-IV) and early PBC (stege I-II), respectively. Based on multicenter studies with large sample sizes, the recently reported GLOBE score and UK-PBC score seem to be superior to previous models and can be applied in patients with different stages of PBC who are already on UDCA therapy, but further external validation may be justified.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816 · cited 2×
“Finally, the Mayo score [10] was reported in 1989, which overcame these limitations and has been widely used in the clinical practice.”
MethodParés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 2×
“In Paris I criteria [13], biochemical response was defined as ALP\3 ULN, aspartate aminotransferase (AST)\2 ULN and bilirubin B17.”
BackgroundCelaya, F. B. (1989) · Anales de Medicina Interna · Cited by 508
Peng, Y., Qi, X., & Guo, X. (2016) · Medicine · doi:10.1097/md.0000000000002877 · Cited by 476
Corpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Kuiper, E. M. M., Hansen, B. E., de Vries, R. A., den Ouden–Muller, J. W., van Ditzhuijsen, T. J. M., Haagsma, E. B., Houben, M. H. M. G., Witteman, B. J. M., van Erpecum, K. J., & van Buuren, H. R. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.003 · Cited by 460
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis
Christensen, E., Neuberger, J., Crowe, J., Altman, D. G., Popper, H., Portmann, B., Doniach, D., Ranek, L., Tygstrup, N., & Williams, R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90213-6 · Cited by 423
Roll, J., Boyer, J. L., Barry, D., & Klatskin, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301063080101 · Cited by 417 · cited 2×
“This study revealed that age, elevated serum bilirubin, hepatomegaly and advanced fibrosis or cirrhosis were independently associated with a poorer prognosis [8].”
BackgroundThe effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis
Corpechot, C., Carrat, F., Bahr, A., Chrétien, Y., Poupon, R.-E., & Poupon, R. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.009 · Cited by 390
Carbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.005 · Cited by 386
Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372 · cited 2×
“In 2010, Toronto criteria were derived from 69 UDCAtreated PBC patients with paired liver biopsies performed approximately 10 years apart [16].”
BackgroundMethodCarbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354 · cited 4×
“[20] developed and validated the UK-PBC score in a cohort of more than 3000 participants, which not only contained variables that defined the treatment response (ALP, transferases and bilirubin after 12 months of UDCA), but also included measures of hepatocellular synthetic function (albumin at baseline) and hepatic f…”
BackgroundMethodInfluentialPrince, M., Chetwynd, A., Newman, W., Metcalf, J. V., & James, O. F. W. (2002) · Gastroenterology · doi:10.1053/gast.2002.36027 · Cited by 348
Corpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Hirschfield, G. M., & Heathcote, E. J. (2010) · Evidence‐Based Gastroenterology and Hepatology · doi:10.1002/9781444314403.ch32 · Cited by 261
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290301 · Cited by 234
Poupon, R. E., Lindor, K. D., Parés, A., Chazouillères, O., Poupon, R., & Heathcote, E. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00192-2 · Cited by 217
Angulo, P., Lindor, K. D., Therneau, T. M., Jorgensen, R. A., Malinchoc, M., Kamath, P. S., & Dickson, E. R. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00020.x · Cited by 203 · cited 2×
“After the introduction of UDCA to treat this disease, Rochester criteria was proposed in 1999 based on PBC patients receiving this therapy [11].”
BackgroundMethodTrivedi, P. J., Lammers, W. J., van Buuren, H. R., Parés, A., Floreani, A., Janssen, H. L. A., Invernizzi, P., Battezzati, P. M., Ponsioen, C. Y., Corpechot, C., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308351 · Cited by 178
Mahl, T. C., Shockcor, W., & Boyer, J. L. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80139-4 · Cited by 163
ter Borg, P. C. J., Schalm, S. W., Hansen, B. E., & van Buuren, H. R. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00699.x · Cited by 160
Diminished survival in asymptomatic primary biliary cirrhosis
Balasubramaniam, K., Grambsch, P. M., Wiesner, R. H., Lindor, K. D., & Dickson, E. R. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)91091-j · Cited by 141
Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis
Springer, J., Cauch-Dudek, K., O'Rourke, K., Wanless, I. R., & Heathcote, E. J. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.00770.x · Cited by 141
Trivedi, P. J., Bruns, T., Cheung, A., Li, K.-K., Kittler, C., Kumagi, T., Shah, H., Corbett, C., Al-Harthy, N., Acarsu, U., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.029 · Cited by 132 · cited 1×
“[21] reported in 2014 that AST/platelet ratio index (APRI) at baseline, and/or after 1 year (APRI-r1) could estimate long-term outcome in PBC patients.”
BackgroundNew simple prognostic score for primary biliary cirrhosis: Albumin‐bilirubin score
Chan, A. W. H., Chan, R., Wong, G. L., Wong, V. W., Choi, P. C. L., Chan, H. L., & To, K. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12938 · Cited by 127
Zhang, L.-N., Shi, T.-Y., Shi, X.-H., Wang, L., Yang, Y.-J., Liu, B., Gao, L.-X., Shuai, Z.-W., Kong, F., Chen, H., et al. (2013) · Hepatology · doi:10.1002/hep.26322 · Cited by 113 · cited 1×
“While most models use biochemical response at 12 months of UDCA treatment, recent reports suggest that evaluation at 6 months may have equivalent predictive performance [31].”
MethodAzemoto, N., Abe, M., Murata, Y., Hiasa, Y., Hamada, M., Matsuura, B., & Onji, M. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0051-9 · Cited by 92
Yang, F., Yang, Y., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Wei, Y., Bian, Z., Sheng, L., Chen, X., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13927 · Cited by 89
Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis
Momah, N., Silveira, M. G., Jorgensen, R., Sinakos, E., & Lindor, K. D. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02678.x · Cited by 77
Kim, R. W., Wiesner, R. H., Poterucha, J. J., Therneau, T. M., Benson, J. T., Krom, R. A. F., & Dickson, R. E. (2000) · Liver Transplantation · doi:10.1053/jlts.2000.6503 · Cited by 52
Singal, A. K., Fang, X., Kaif, M., Hasanin, M., McGuire, B. M., Kuo, Y., & Wiesner, R. H. (2016) · Transplant International · doi:10.1111/tri.12877 · Cited by 44
Natural history and management of primary biliary cirrhosis
Kumagi, T., & Al‐Harthy, N. (2012) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s25998 · Cited by 37
Recent advances in the diagnosis and treatment of primary biliary cholangitis
Huang, Y.-Q. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i33.1419 · Cited by 31
Changing nomenclature for PBC from “primary biliary cirrhosis” to “primary biliary cholangitis”
Tanaka, A., Takikawa, H., Miwa, H., Shimosegawa, T., Mochida, S., & Koike, K. (2016) · Hepatology Research · doi:10.1111/hepr.12729 · Cited by 17
Changing nomenclature for PBC from "Primary Biliary Cirrhosis" to "Primary Biliary Cholangitis".
Tanaka, A., Takikawa, H., Mochida, S., Koike, K., Miwa, H., & Shimosegawa, T. (2016) · PubMed · doi:10.11405/nisshoshi.113.1165 · Cited by 3
Cited by
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Self-citationCurrent epidemiology and clinical characteristics of autoimmune liver diseases in South Korea
Jeong, S. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0066 · Cited by 35
Cholankeril, G. T., González, H. C., Satapathy, S. K., Gonzalez, S. A., Hu, M., Khan, M. A., Yoo, E. R., Li, A. A., Kim, D., Nair, S. P., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.017 · Cited by 37
Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)
You, H., Duan, W., Li, S., Lv, T., Chen, S., Lu, L., Ma, X., Han, Y., Nan, Y., Xu, X., et al. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00347 · Cited by 46
Self-citation
Metadata
- Authors
- Chen, S., Duan, W., You, H., & Jia, J.
- Affiliations
- Capital Medical University (CN)
- Corresponding author
- Jia, Jidong
- Venue
- Hepatology International
- Published
- 2017-09
- Volume
- 11
- Issue
- 5
- Pages
- 412-418
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- OpenAlex
- W2755775439
- Cited by
- 20
- References
- 41
- Citations by year
- 2026: 2 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 4
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hepatology International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science and Technology Major Project (2013ZX10002004)
- Key Project from Beijing Municipal Science and Technology Commission (D121100003912003)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, prognostic model, Mayo score, Paris criteria, GLOBE score, ursodeoxycholic acid, end-stage liver disease, disease staging, long-term outcome prediction, external validation
- MeSH terms
- Humans, Liver Cirrhosis, Biliary, Models, Theoretical, Prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.